ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Violation of NASDAQ rule

<< Previous

Bullboard Posts

Next >>

Post by goldtechon Jul 09, 2024 1:15pm

149 Views

Post# 36124655

Violation of NASDAQ rule

Nasdaq company is required to promptly disclose "any material information that would reasonably be expected to affect the value of its securities or influence investors' decisions." The disclosure may be made through any method that complies with the SEC's Regulation FD (Fair Disclosure), including a broadly ...Jan 1, 2024

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario